Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Virology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SAMHD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SAMHD1 Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for dNTPase activity assays. |
View SAMHD1 Products |
| Gene Delivery | SAMHD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to model chemotherapy resistance. |
View SAMHD1 Products |
| Benchmark Ab | Anti-SAMHD1 Recombinant Antibody Recombinant positive control for Western Blot and Flow Cytometry. |
View SAMHD1 Products |
| Validator | SAMHD1 siRNA Set For knockdown verification in leukemia and solid tumor cell lines. |
View SAMHD1 Products |
| Related Target A | RRM1 Ribonucleotide reductase large subunit; co-regulates intracellular dNTP pools and synergizes with SAMHD1 inhibition. |
View RRM1 Products |
| Related Target B | CDK1 Cyclin-dependent kinase 1; phosphorylates SAMHD1 at Thr592, regulating its dNTPase and antiviral functions. |
View CDK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Consistency | High-purity recombinant SAMHD1 with verified sequence integrity and low endotoxin levels, ensuring reproducible dNTPase assays. |
| Phosphorylation-State Modeling | Availability of specific mutant constructs (e.g., T592D phosphomimetic or T592A non-phosphorylatable) to dissect regulatory pathways. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive controls included in the catalog. |
| False Positives in Knockdown | Multi-sequence validated siRNA pools included for highly specific target knockdown verification. |
Live SAMHD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SAMHD1 therapeutics is intensifying, with major players shifting focus from traditional antiviral restriction studies to oncology indications, specifically targeting chemotherapy resistance. SAMHD1 acts as a dNTPase that degrades the active triphosphorylated metabolites of nucleoside analogs such as cytarabine (Ara-C), decitabine, and gemcitabine. By rapidly depleting these active drug forms within cancer cells, SAMHD1 directly drives clinical drug resistance in acute myeloid leukemia (AML) and various solid tumors.
As first-generation small-molecule inhibitors of SAMHD1 reach preclinical and early clinical validation, the next wave of R&D is targeting the synergistic co-administration of SAMHD1 inhibitors alongside standard-of-care nucleoside chemotherapies. Additionally, targeting the CDK1/2-mediated phosphorylation pathway of SAMHD1 represents a novel avenue to modulate its dNTPase activity in immunological and oncology contexts.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Karolinska Institutet, Emory University, Biotech Startups | Acute Myeloid Leukemia (AML), Refractory Solid Tumors | High-throughput dNTPase activity screening (Requires highly pure, active recombinant SAMHD1 protein) |
| Vpx-mediated Degraders | Academic Research Centers | HIV-1 Adjunct Therapy, Cancer Immunotherapy | Protein degradation assays (Requires sequence-verified SAMHD1 for transfection and Western Blot validation) |
| Combination Therapies | Oncology Consortia | Gemcitabine/Ara-C Resistant Cancers | Cell-based resistance reversal assays (Requires SAMHD1 Lentivirus for stable cell line construction) |